Filing Flows

Filing Flows › Companies › Palisade Bio › Cash flow

Palisade Bio cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$7.6M in Q2 2026 · −$18.2M over twelve months

Operating cash flow−$7.6M
Free cash flow−$7.6M

Analysis

In Q2 2026, Palisade Bio generated −$7.6M of operating cash flow. That is $5.8M less than in Q2 2025 (−$1.8M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$18.2M; the largest uses were operating cash flow ($18.2M), net borrowing (+) / repaid (−) ($311K); besides operations, cash came from shares issued ($132M), other financing ($6.8M); the cash balance rose by $120M.

Operating cash flow was −$7.6M against net income of −$10.6M. The largest differences: stock-based pay +$4.8M, prepaid and other assets −$937K, payables −$518K.

Free cash flow

Palisade Bio: free cash flow by quarterPalisade Bio: free cash flow by quarter−$3.1MQ3 2024−$2.4MQ4 2024−$2.3MQ1 2025−$1.8MQ2 2025−$3.6MQ3 2025−$3.1MQ4 2025−$3.9MQ1 2026−$7.6MQ2 2026
Operating cash flow less capital spending.
Palisade Bio: operating cash flow against capital spendingPalisade Bio: operating cash flow against capital spendingOperating cash flowCapital spending−$3.1M$0Q3 2024−$2.4M$0Q4 2024−$2.3M$0Q1 2025−$1.8M$0Q2 2025−$3.6M$0Q3 2025−$3.1M$0Q4 2025−$3.9M$0Q1 2026−$7.6M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$7.6M, Capital spending $0.

Capital allocation, year by year

Palisade Bio: where the cash came from (up) and went (down), by fiscal yearPalisade Bio: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsFY2021: Operating cash flow −$14.8MFY2021: Net borrowing −$183KFY2021: Shares issued $25.1MFY2021: Acquisitions −$3.3M$25.1MFY2021FY2022: Operating cash flow −$13.4MFY2022: Shares issued $14.4MFY2022: Capital spending −$10K$14.4MFY2022FY2023: Operating cash flow −$11.1MFY2023: Net borrowing −$391KFY2023: Shares issued $9.4MFY2023: Capital spending −$4K$9.4MFY2023FY2024: Operating cash flow −$12.2MFY2024: Net borrowing −$426KFY2024: Shares issued $8.4M$8.4MFY2024FY2025: Operating cash flow −$10.8MFY2025: Net borrowing −$320KFY2025: Shares issued $128M$128MFY2025
Over these 5 years operating cash flow totalled −$62.3M; the largest uses were operating cash flow ($62.3M) and acquisitions ($3.3M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$125M
Debtnone
Net cash$125M
Cash runway6.9 years

Palisade Bio is burning cash: its operations consume cash, a free cash flow of −$18.2M a year at the current rate against $125M of cash and investments: a runway of about 6.9 years before any new financing.

Where the cash came from and went

Palisade Bio: sources (+) and uses (−) of cash, Q2 2026Palisade Bio: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$7.6MCash drawn (+) / kept (−)$7.5MOther financing$147K
Palisade Bio: sources (+) and uses (−) of cash, TTM to Q2 2026Palisade Bio: sources (+) and uses (−) of cash, TTM to Q2 2026Shares issued$132MCash drawn (+) / kept (−)−$120MOperating cash flow−$18.2MOther financing$6.8MNet borrowing (+) / repaid (−)−$311K

From profit to cash

Palisade Bio: net income to operating cash flow, Q2 2026Palisade Bio: net income to operating cash flow, Q2 2026Net income−$10.6MStock-based pay$4.8MPayables−$518KEmployee-related liabilities$153KPrepaid and other assets−$937KOperating cash flow−$7.6M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$7.6M——$7.5M−$7.6M
Q1 2026−$3.9M−$71K$3.2M$757K−$3.9M
Q4 2025−$3.1M−$140K$128M−$128M−$3.1M
Q3 2025−$3.6M−$100K—$190K−$3.6M
Q2 2025−$1.8M——$1.8M−$1.8M
Q1 2025−$2.3M−$80K—$2.6M−$2.3M
Q4 2024−$2.4M−$156K$4.4M−$1.8M−$2.4M
Q3 2024−$3.1M−$112K—$3.3M−$3.1M

Palisade Bio: income statement and cash flow

Palisade Bio, Q2 2026: revenue $500K. The chart follows the revenue to costs, profit and cash.

Palisade Bio: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.